Per-Göran Gillberg
Director/Board Member presso ALZINOVA AB
Profilo
Per-Göran Gillberg is the founder of Albireo AB, founded in 1998, where he holds the title of Vice President-Development.
He was also the founder of Albireo Pharma, Inc., founded in 2003, where he also held the title of Vice President-Development.
Dr. Gillberg's current jobs include being an Independent Director at Alzinova AB since 2020 and an Independent Director at Dicot AB since 2021.
Dr. Gillberg's former jobs included being a Pharmacology Director at Pharmacia & Upjohn, Inc., a Director at Karolinska Institutet, a Principal at AstraZeneca PLC, a Principal at Pharmacia AB, the Head-Clinical Development at KABI-AM, and a Vice President-Development at Albireo Ltd.
and Albireo Pharma, Inc.Dr. Gillberg's education included a graduate degree and a doctorate from the University of Uppsala.
Posizioni attive di Per-Göran Gillberg
| Società | Posizione | Inizio |
|---|---|---|
| ALZINOVA AB | Director/Board Member | 01/01/2020 |
| DICOT AB | Director/Board Member | 27/05/2021 |
Albireo AB
 Albireo AB Pharmaceuticals: MajorHealth Technology Albireo AB operates as a biopharmaceutical company, which focuses on the development and potential commercialization of novel bile acid modulators. It helps treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The company was founded by Per-Göran Gillberg and Jan Mattsson and is headquartered in Göteborg, Sweden. | Founder | 01/01/1998 |
Precedenti posizioni note di Per-Göran Gillberg
| Società | Posizione | Fine |
|---|---|---|
| ALBIREO PHARMA, INC. | Corporate Officer/Principal | - |
| ALBIREO PHARMA, INC. | Founder | - |
| Karolinska Institutet | Director/Board Member | - |
| Pharmacia AB | Corporate Officer/Principal | - |
| Pharmacia & Upjohn, Inc. | Corporate Officer/Principal | - |
Formazione di Per-Göran Gillberg
| University of Uppsala | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| DICOT AB | Health Technology |
| ALZINOVA AB | Health Technology |
| Aziende private | 6 |
|---|---|
| Pharmacia & Upjohn, Inc. | Health Technology |
| Pharmacia AB | Health Technology |
| KABI-AM | Consumer Services |
Albireo Ltd.
 Albireo Ltd. Pharmaceuticals: MajorHealth Technology Albireo Ltd. develops therapies that address medical needs in the gastrointestinal and liver disease area. It is a biotechnology company that develops therapies that address unmet medical needs in the gastrointestinal area and liver disease area. The firm's programs include Cholestatic Liver Diseases; Bile Acid Mal-absorption; Type 2 Diabetes Mellitus; Atopic Dermatitis and Psoriasis; and Post-Operative Adhesions. The company was founded by Jan Peter Mattsson in February 2008 and is headquartered in London, the United Kingdom. | Health Technology |
Albireo AB
Albireo AB Pharmaceuticals: MajorHealth Technology Albireo AB operates as a biopharmaceutical company, which focuses on the development and potential commercialization of novel bile acid modulators. It helps treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The company was founded by Per-Göran Gillberg and Jan Mattsson and is headquartered in Göteborg, Sweden. | Health Technology |
Albireo Pharma, Inc.
 Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA. | Health Technology |
- Borsa valori
- Insiders
- Per-Göran Gillberg
